Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):112-9. doi: 10.1177/1074248409358408. Epub 2010 Mar 3.
Recent evidence from a number of in vitro and in vivo studies in isolated cells and animal models has suggested that the cytochrome P450 (CYP450) pathway of arachidonic acid (AA) metabolism produces potent cardioprotective metabolites that markedly reduce reversible (myocardial stunning) and irreversible (infarct size [IS]) injury in the ischemic/reperfused heart. The major players in this protective response appear to be the AA metabolites including the regioisomers of 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs). The present review article will discuss the beneficial effects of the EETs on myocardial stunning and IS reduction and consider some of the signaling pathways and cellular mechanisms by which the EETs produce their beneficial effects and the possible therapeutic benefits that may result from activation of this pathway. The results discussed in this review are taken from experiments obtained from 3 diverse species in different laboratories: the mouse, rat, and dog, in which the results were nearly identical qualitatively and quantitatively, suggesting that these findings are likely to be extrapolated to man as well.
最近的一些体外和体内研究在分离的细胞和动物模型中表明,花生四烯酸(AA)代谢的细胞色素 P450(CYP450)途径产生有效的心脏保护代谢物,可明显减少缺血/再灌注心脏中的可逆性(心肌顿抑)和不可逆性(梗死面积[IS])损伤。这种保护反应的主要参与者似乎是 AA 代谢物,包括 5,6-、8,9-、11,12-和 14,15-环氧二十碳三烯酸(EETs)的区域异构体。本文综述将讨论 EETs 对心肌顿抑和 IS 减少的有益作用,并考虑 EETs 产生其有益作用的一些信号通路和细胞机制,以及激活该途径可能带来的潜在治疗益处。本文讨论的结果来自于在不同实验室的 3 个不同物种(小鼠、大鼠和狗)的实验中获得,结果在定性和定量上几乎完全相同,这表明这些发现很可能也适用于人类。